Replies to post #3485 on Titan Pharmaceuticals Inc (TTNP)

[TRUISM]

I especially like this:

3-D printing makes the bioresorbable filament technology practical because it allows for customization and decentralized manufacturing, said Louisiana Tech biomedical engineering professor David Mills in the statement: "Currently, embedding of additives in plastic requires industrial-scale facilities to ensure proper dispersion throughout the extruded plastic. Our method enables dispersion on a tabletop scale, allowing researchers to easily customize additives to the desired levels. There are not even any industrial processes for antibiotics or special drug delivery as injection molding currently focuses more on colorants and cosmetic properties."

Device companies such as Abbott ($ABT) are already selling and/or developing bioresorbable drug-eluting stents. Could bioresorbable drug-eluting catheters or implants be next?

They would certainly be to the industry's benefit. For instance, Titan Pharmaceuticals ($TTNP) and Braeburn Pharmaceuticals are working together to commercialize a clinical stage implant for the treatment of opioid dependence. The product was rejected by FDA in May. One of the FDA's requests for future approval was "human factors testing of the training associated with Probuphine's insertion and removal," according to sister publication FierceBiotech.

TRUTH